WHO ICTRP trial
InCroMiel I
RPCEC00000050 · Registro Público Cubano de Ensayos Clínicos (RPCEC) · Not Recruiting
Key facts
| Trial ID | RPCEC00000050 |
|---|---|
| Public title | InCroMiel I |
| Scientific title | Use of Alpha Interferon in the treatment of Chronic Myeloid Leukaemia. |
| Primary sponsor | Center for Genetic Engineering and Biothecnology (CIGB), in Havana. |
| Secondary sponsors | Not applicable |
| Registry | Registro Público Cubano de Ensayos Clínicos (RPCEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | Cuba |
| Conditions | Chronic Myeloid Leukemia.;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid;Leukemia;Myeloproliferative Disorders;Bone Marrow Diseases;Hemic Diseases |
| Interventions | Induction: Busulfan (BU), Cyclophosphamide (CFM) and/or Hydroxyurea (HU) considering the patient in remission when lecucocitos keep count 5 to 10x109 / L for more than 4 weeks. Maintenance: IFN-alfa 2b will be administered at a standard… |
| Registration date | Dec 24, 2009 |
| Target size | 60 |
| Secondary IDs | IG/INR/LM/9801 |
| Registry page | rpcec.sld.cu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: